News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
ICR and life sciences company QBiotics launch new collaboration to study potential cancer drug derived from rainforest tree species
Scientists at The Institute of Cancer Research, London, are collaborating with life sciences company QBiotics to unravel the molecular and cellular mechanisms of a potential new cancer drug.
ICR scientists unveil AI-powered platform that helps researchers speed up biomarker discoveries for personalised cancer treatment
An ICR team has unveiled a cutting-edge research platform powered by artificial intelligence (AI) that will revolutionise cancer research by allowing researchers to integrate and analyse large and complex clinical trial datasets, speeding up the discovery of new cancer biomarkers.
New study confirms hormone’s role in post-menopausal breast cancer risk
In the largest and most comprehensive study of its kind, researchers have provided further evidence that a hormone responsible for regulating breast development acts as a risk factor for breast cancer in post-menopausal women.
£5.5m research funding to transform bowel cancer care
Scientists from The Institute of Cancer Research, London, are part of a team of international researchers who have secured £5.5million in funding to find smarter, kinder treatments for people living with bowel cancer.
-carousel-945x581.jpg?sfvrsn=d29fb9e9_2 "A high magnification image of ovarian clear cell carcinoma (photo: Nephron) carousel 945x581")
Newly identified biomarker could improve treatment for people with rare type of ovarian cancer
Scientists at The Institute of Cancer Research, London, have identified a gene that affects how ovarian clear cell carcinoma (OCCC) could respond to a new class of drug called ATR inhibitors.
Innovative neuroblastoma research could lead to tailored treatments for high-risk patients
New research has provided insight into the biological mechanisms that may contribute to poor outcomes in certain cases of neuroblastoma – a cancer that develops in nerve tissue and primarily affects children.
New AI technology could bring cancer drugs to patients in half the current time
Scientists have developed a revolutionary AI ‘fingerprint’ technology that can accurately show how cancer cells respond to new drugs, by simply observing changes to their shape.
Remembering former ICR Chief Executive Professor Peter Garland
The ICR reflects on the legacy of Professor Peter Garland CBE, who served as Chief Executive from 1989 to 1999 and died on 5 March.
.png?sfvrsn=38d02ad6_1 "PW head and shoulders in garden_expand.jpg (1)")
The ICR’s Professor Paul Workman elected Fellow of the American Association of Cancer Research Academy
The Institute of Cancer Research, London, is delighted to announce that Professor Paul Workman has been elected as a Fellow of The American Association for Cancer Research (AACR) Academy.
New collaboration to advance innovative drugs for aggressive childhood brain tumours
Scientists at The Institute of Cancer Research, London, are partnering with Revolver Therapeutics to accelerate the development of pioneering drugs for treating incurable childhood brain tumours.
£1.5million funding boost to help unlock the genetic secrets of aggressive neuroblastoma
Scientists from The Institute of Cancer Research, London, will be part of a team of international researchers who have secured funding to study the genetic secrets of childhood cancer neuroblastoma.
.jpg?sfvrsn=999b1809_2 "Clinical trials pills bottles (16.9)")
Genetic factors likely to determine which patients will benefit from new prostate cancer combination therapy
Researchers have uncovered several biological signs that may determine how metastatic castration-resistant prostate cancer (mCRPC) responds to a new treatment combination.
